Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rxo (RXO) Operating Expenses (2021 - 2025)

Historic Operating Expenses for Rxo (RXO) over the last 5 years, with Q4 2025 value amounting to $200.0 million.

  • Rxo's Operating Expenses fell 825.69% to $200.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $832.0 million, marking a year-over-year increase of 2492.49%. This contributed to the annual value of $832.0 million for FY2025, which is 2492.49% up from last year.
  • Latest data reveals that Rxo reported Operating Expenses of $200.0 million as of Q4 2025, which was down 825.69% from $208.0 million recorded in Q3 2025.
  • Over the past 5 years, Rxo's Operating Expenses peaked at $218.0 million during Q4 2024, and registered a low of $130.0 million during Q3 2021.
  • Moreover, its 5-year median value for Operating Expenses was $154.5 million (2022), whereas its average is $167.3 million.
  • As far as peak fluctuations go, Rxo's Operating Expenses plummeted by 1325.3% in 2023, and later soared by 4931.51% in 2024.
  • Rxo's Operating Expenses (Quarter) stood at $152.0 million in 2021, then increased by 1.97% to $155.0 million in 2022, then fell by 5.81% to $146.0 million in 2023, then soared by 49.32% to $218.0 million in 2024, then dropped by 8.26% to $200.0 million in 2025.
  • Its Operating Expenses stands at $200.0 million for Q4 2025, versus $208.0 million for Q3 2025 and $214.0 million for Q2 2025.